Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance.

Androgen receptor (AR) signaling continues to play a dominant role in all stages of prostate cancer (PC), including castration-resistant prostate cancers (CRPC) that have developed resistance to second-generation AR antagonists such as enzalutamide.